Please check your internet connection and try again.
## Sompraz hp
### Overview
Sompraz hp is a fixed-dose combination product containing pantoprazole, amoxicillin, and clarithromycin, used for the eradication of *Helicobacter pylori* (*H. pylori*). Pantoprazole is a proton pump inhibitor (PPI), while amoxicillin and clarithromycin are antibiotics.
### Primary Indications
Treatment of *Helicobacter pylori* infection in patients with peptic ulcer disease or a history of peptic ulcer disease.
### Adult Dosing
The typical adult dose is one Sachet hp orally twice daily for 7 days. Each Sachet hp contains pantoprazole 40 mg, amoxicillin 1000 mg, and clarithromycin 500 mg. The dose should be taken as prescribed, usually before breakfast and before the evening meal.
### Pediatric Dosing
Pediatric dosing for Sompraz hp is not established. Dosing for individual components in pediatric patients may vary based on age, weight, and indication.
### Dose Adjustments
No specific dose adjustments are typically required for renal or hepatic impairment when using the fixed-dose combination, as the individual components have specific recommendations that are incorporated into the fixed dose regimen. However, caution should be exercised in severe renal or hepatic impairment.
### Contraindications
* Hypersensitivity to pantoprazole, amoxicillin, clarithromycin, or any component of the formulation.
* History of hypersensitivity to other penicillins, cephalosporins, or macrolides.
* Concomitant use with rifampin or ergot alkaloids.
* Patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use.
### Adverse Effects
Common adverse effects may include diarrhea, nausea, abdominal pain, headache, dysgeusia (altered taste), rash, and changes in liver enzymes. Serious adverse effects can include C. difficile-associated diarrhea, allergic reactions (including anaphylaxis), and QT prolongation (with clarithromycin).
### Key Drug Interactions
* **Pantoprazole:** May decrease the absorption of drugs requiring an acidic environment (e.g., ketoconazole, itraconazole, certain HIV protease inhibitors). May increase levels of certain drugs metabolized by CYP2C19 (e.g., clopidogrel, warfarin).
* **Clarithromycin:** Potent inhibitor of CYP3A4. May increase serum concentrations of drugs metabolized by CYP3A4 (e.g., statins, calcium channel blockers, benzodiazepines, certain immunosuppressants, colchicine). Increased risk of myopathy and rhabdomyolysis with statins. Contraindicated with rifampin, ergot alkaloids, cisapride, pimozide, and lovastatin/simvastatin.
* **Amoxicillin:** May decrease the efficacy of oral contraceptives. May interfere with urine glucose tests.
### Monitoring
* Monitor for signs and symptoms of C. difficile-associated diarrhea.
* Monitor for signs of hypersensitivity reactions.
* Monitor liver function tests, particularly in patients with pre-existing liver disease.
* Monitor for drug interactions, especially with clarithromycin's CYP3A4 inhibition.
* Assess for *H. pylori* eradication status via appropriate testing after completion of therapy.
### Clinical Pearls
* This combination therapy is designed for a specific duration (usually 7 days) to maximize *H. pylori* eradication rates.
* Ensure patients understand the importance of completing the full course of treatment, even if they feel better.
* Advise patients to take the medication as directed, typically before meals, to optimize absorption and efficacy.
* Consider potential allergies to penicillins or macrolides before prescribing.
* When amoxicillin or clarithromycin are used individually, resistance rates can impact efficacy. The fixed-dose combination relies on established regimens to overcome resistance.
***
**Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for definitive patient management decisions. Dosing and recommendations may vary based on local protocols and individual patient factors.
